Low-molecular-weight heparin (LMWH) has several advantages over conventional unfractionated heparin in the prevention and treatment of deep venous thrombosis (DVT).1 Enoxaparin is a LMWH approved for several indications such as unstable angina, non–Q-wave myocardial infarction, and DVT.2,3 There are reports of epidural or spinal hematomas after spinal puncture in patients being treated with enoxaparin that can result in permanent paralysis.2 We describe a patient who developed a debilitating soft tissue hematoma after femoral venipunctures while being treated with enoxaparin.